Xeris Biopharma Holdings, Inc.
XERS
$4.88
-$0.27-5.24%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 60.10M | 54.27M | 48.07M | 40.64M | 44.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.10M | 54.27M | 48.07M | 40.64M | 44.39M |
| Cost of Revenue | 9.48M | 13.59M | 7.79M | 5.97M | 7.57M |
| Gross Profit | 50.62M | 40.68M | 40.28M | 34.67M | 36.82M |
| SG&A Expenses | 34.04M | 44.97M | 39.99M | 38.38M | 37.57M |
| Depreciation & Amortization | 2.71M | 2.71M | 2.71M | 2.71M | 2.71M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.32M | 67.16M | 56.25M | 54.88M | 54.23M |
| Operating Income | 7.78M | -12.89M | -8.19M | -14.25M | -9.84M |
| Income Before Tax | -5.11M | -19.06M | -14.26M | -18.67M | -13.63M |
| Income Tax Expenses | 0.00 | -3.32M | 749.00K | 307.00K | -236.00K |
| Earnings from Continuing Operations | -5.11M | -15.74M | -15.01M | -18.98M | -13.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.11M | -15.74M | -15.01M | -18.98M | -13.39M |
| EBIT | 7.78M | -12.89M | -8.19M | -14.25M | -9.84M |
| EBITDA | 10.80M | -9.88M | -5.20M | -11.21M | -6.78M |
| EPS Basic | -0.03 | -0.11 | -0.10 | -0.14 | -0.10 |
| Normalized Basic EPS | 0.00 | -0.08 | -0.06 | -0.09 | -0.07 |
| EPS Diluted | -0.03 | -0.11 | -0.10 | -0.14 | -0.10 |
| Normalized Diluted EPS | 0.00 | -0.08 | -0.06 | -0.09 | -0.07 |
| Average Basic Shares Outstanding | 149.09M | 148.99M | 148.35M | 140.51M | 138.12M |
| Average Diluted Shares Outstanding | 149.09M | 148.99M | 148.35M | 140.51M | 138.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
